Literature DB >> 2295482

Use of seclusion and restraint in public psychiatric hospitals: patient characteristics and facility effects.

B B Way1, S M Banks.   

Abstract

Use of seclusion and restraint in 23 adult public psychiatric hospitals in New York State was examined by comparing demographic and diagnostic characteristics of 657 patients who were secluded or restrained during a four-week period with characteristics of 22,939 patients who were not. Logit analysis was used to calculate the probability of seclusion and restraint of individual patients with various combinations of characteristics. Characteristics associated with high probabilities included age less than 26 years, length of stay from 30 to 365 days, involuntary legal status, female gender, a diagnosis of mental retardation, and residence in a hospital with a high rate of seclusion and restraint. The rate of seclusion and restrain in the 23 hospitals ranged from .4 to 9.4 percent of patients. Both patient characteristics and the hospital of residence were needed to explain the case-by-case probability of a patient's being secluded or restrained.

Entities:  

Mesh:

Year:  1990        PMID: 2295482     DOI: 10.1176/ps.41.1.75

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  15 in total

Review 1.  Seclusion and restraint for people with serious mental illnesses.

Authors:  E Sailas; M Fenton
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  A 15-year national follow-up: legislation is not enough to reduce the use of seclusion and restraint.

Authors:  Alice Keski-Valkama; Eila Sailas; Markku Eronen; Anna-Maija Koivisto; Jouko Lönnqvist; Riittakerttu Kaltiala-Heino
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-27       Impact factor: 4.328

3.  Who are the restrained and secluded patients: a 15-year nationwide study.

Authors:  Alice Keski-Valkama; Eila Sailas; Markku Eronen; Anna-Maija Koivisto; Jouko Lönnqvist; Riittakerttu Kaltiala-Heino
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-10-21       Impact factor: 4.328

4.  A cross-sectional prospective study of seclusion, restraint and involuntary medication in acute psychiatric wards: patient, staff and ward characteristics.

Authors:  Tonje Lossius Husum; Johan Håkon Bjørngaard; Arnstein Finset; Torleif Ruud
Journal:  BMC Health Serv Res       Date:  2010-04-06       Impact factor: 2.655

5.  Listening to the Patient Perspective: Psychiatric Inpatients' Attitudes Towards Physical Restraint.

Authors:  Yaniv Spinzy; Saed Maree; Aviv Segev; Gadi Cohen-Rappaport
Journal:  Psychiatr Q       Date:  2018-09

6.  Reducing restraint use in a public psychiatric inpatient service.

Authors:  Robert E McCue; Leonel Urcuyo; Yehezkel Lilu; Teresa Tobias; Michael J Chambers
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

7.  Do patient and ward-related characteristics influence the use of coercive measures? Results from the EUNOMIA international study.

Authors:  Lucie Kalisova; Jiri Raboch; Alexander Nawka; Gaia Sampogna; Libor Cihal; Thomas W Kallert; Georgi Onchev; Anastasia Karastergiou; Valeria Del Vecchio; Andrzej Kiejna; Tomasz Adamowski; Francisco Torres-Gonzales; Jorge A Cervilla; Stephan Priebe; Domenico Giacco; Lars Kjellin; Algirdas Dembinskas; Andrea Fiorillo
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-04-16       Impact factor: 4.328

8.  Physical control of patients on an inpatient setting: forensic vs. civil populations.

Authors:  K Heilbrun; G G Golloway; V E Shoukry; D Gustafson
Journal:  Psychiatr Q       Date:  1995

9.  Differences in seclusion rates between admission wards: does patient compilation explain?

Authors:  W A Janssen; E O Noorthoorn; H L I Nijman; L Bowers; A W Hoogendoorn; A Smit; G A M Widdershoven
Journal:  Psychiatr Q       Date:  2013-03

10.  "Coercion Experience Scale" (CES)--validation of a questionnaire on coercive measures.

Authors:  Jan Bergk; Erich Flammer; Tilman Steinert
Journal:  BMC Psychiatry       Date:  2010-01-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.